| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
101,580,000 |
| Market
Cap: |
910.16(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.28 - $27.36 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
265 |
72,037 |
75,959 |
137,146 |
| Total Sell Value |
$2,253 |
$865,395 |
$950,555 |
$2,864,218 |
| Total People Sold |
1 |
8 |
9 |
10 |
| Total Sell Transactions |
1 |
12 |
15 |
30 |
| End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bhanji Muna |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,203 |
|
- |
|
| Goodman Jesse |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,453 |
|
- |
|
| Verwiel Frank |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
25,948 |
|
- |
|
| Chase William J |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
34,693 |
|
- |
|
| Goff Brian |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
23,409 |
|
- |
|
| Cohen Fred E |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
57,453 |
|
- |
|
| Bhanji Muna |
|
– • – |
2025-04-29 |
4 |
AS |
$8.50 |
$2,253 |
D/D |
(265) |
19,203 |
|
1% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-03-04 |
4 |
S |
$8.99 |
$6,104 |
D/D |
(679) |
95,369 |
|
9% |
|
| Basta James |
EVP, General Counsel |
• – – |
2025-03-04 |
4 |
S |
$8.99 |
$23,122 |
D/D |
(2,572) |
111,925 |
|
9% |
|
| Leonard John M. |
President and CEO |
• • – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
136,000 |
1,077,115 |
|
- |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
59,640 |
|
- |
|
| Dulac Edward J Iii |
EVP, Chief Financial Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
47,200 |
113,524 |
|
- |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
96,048 |
|
- |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
43,200 |
130,866 |
|
- |
|
| Schultes Birgit C |
EVP, Chief Scientific Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,600 |
105,215 |
|
- |
|
| Basta James |
EVP, General Counsel |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
114,497 |
|
- |
|
| Bhanji Muna |
|
– • – |
2025-01-29 |
4 |
AS |
$9.97 |
$2,642 |
D/D |
(265) |
19,468 |
|
-18% |
|
| Schultes Birgit C |
EVP, Chief Scientific Officer |
• – – |
2025-01-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
67,615 |
|
-6% |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-01-03 |
4 |
S |
$12.18 |
$16,711 |
D/D |
(1,372) |
45,640 |
|
33% |
|
| Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
• – – |
2025-01-03 |
4 |
S |
$12.18 |
$109,206 |
D/D |
(8,966) |
77,388 |
|
33% |
|
| Hicks Derek |
EVP, Chief Business Officer |
• – – |
2025-01-03 |
4 |
S |
$12.18 |
$79,194 |
D/D |
(6,502) |
59,878 |
|
33% |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2025-01-03 |
4 |
S |
$12.18 |
$116,404 |
D/D |
(9,557) |
87,666 |
|
33% |
|
| Basta James |
EVP, General Counsel |
• – – |
2025-01-03 |
4 |
S |
$12.18 |
$86,161 |
D/D |
(7,074) |
74,497 |
|
33% |
|
| Leonard John M. |
President and CEO |
• • – |
2025-01-03 |
4 |
S |
$12.18 |
$326,509 |
D/D |
(26,807) |
941,115 |
|
33% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-01-03 |
4 |
S |
$12.18 |
$90,400 |
D/D |
(7,422) |
64,048 |
|
33% |
|
286 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.65 (7.82%) 
